MicroRNA‑210 is upregulated by hypoxia-inducible factor‑1α in the stromal cells of giant cell tumors of bone

Guo,Shibing; Bai,Rui; Liu,Wanlin; Zhao,Aiqing; Zhao,Zhenqun; Wang,Yuxin; Wang,Yong; Zhao,Wei; Wang,Wenxuan

doi:10.3892/mmr.2015.4170

MicroRNA‑210 is upregulated by hypoxia-inducible factor‑1α in the stromal cells of giant cell tumors of bone

Authors:
- Shibing Guo
- Rui Bai
- Wanlin Liu
- Aiqing Zhao
- Zhenqun Zhao
- Yuxin Wang
- Yong Wang
- Wei Zhao
- Wenxuan Wang
View Affiliations

Affiliations: Department of Orthopedics, Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China, Department of Radiology, First Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, P.R. China
Published online on: August 3, 2015 https://doi.org/10.3892/mmr.2015.4170
Pages: 6185-6192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To date, little is known regarding the molecular mechanisms underlying the deregulation of the giant cell tumor of bone (GCTB). Hypoxia has been confirmed to be a characteristic observed in a variety of types of cancer, and a pivotal role for hypoxia‑inducible factor-1α (HIF‑1α) has previously been indicated in the hypoxia adaptation of GCTBs. However, another key regulator, microRNA (miR)‑210, which is closely correlated with HIF‑1α, has not previously been identified in GCTBs. The present study therefore selected miR‑210, the most significantly upregulated miRNA in hypoxic subtypes of cancer, for investigation in GCTB tissues. Reverse transcription-quantitative polymerase chain reaction was used to evaluate miR‑210 expression levels in GCTB tissues and primary GCTB stromal cells. It was revealed that miR‑210 and HIF‑1α were upregulated in GCTB specimens and in primary GCTB stromal cells under hypoxia, and a positive correlation was identified between the two molecules. Furthermore, the promotion of miR‑210 expression in primary GCTB stromal cells by hypoxia was HIF‑1α‑dependent. To the best of our knowledge, the present study was the first to identify the overexpression of miR‑210 in an HIF‑1α‑dependent manner in GCTB specimens, suggesting an adaptive response to hypoxia in GCTB.

View Figures

View References

1	Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–114. 1987.PubMed/NCBI
2	Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M and Tomeno B: Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop. 22:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
3	Gamberi G, Serra M, Ragazzini P, et al: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356. 2003.PubMed/NCBI
4	Miszczyk L, Wydmanski J and Spindel J: Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys. 49:1239–1242. 2001. View Article : Google Scholar : PubMed/NCBI
5	Olivera P, Perez E, Ortega A, et al: Estrogen receptor expression in giant cell tumors of the bone. Hum Pathol. 33:165–169. 2002. View Article : Google Scholar : PubMed/NCBI
6	Melillo G: Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res. 4:601–605. 2006. View Article : Google Scholar : PubMed/NCBI
7	Lin SC, Liao WL, Lee JC and Tsai SJ: Hypoxia-regulated gene network in drug resistance and cancer progression. Exp Biol Med (Maywood). 239:779–792. 2014. View Article : Google Scholar
8	Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pflugers Arch. 450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
9	Licausi F, Weits DA, Pant BD, Scheible WR, Geigenberger P and van Dongen JT: Hypoxia responsive gene expression is mediated by various subsets of transcription factors and miRNAs that are determined by the actual oxygen availability. New Phytol. 190:442–456. 2011. View Article : Google Scholar
10	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
11	Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
13	Pouysségur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
15	Blancher C, Moore JW, Talks KL, Houlbrook S and Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60:7106–7113. 2000.
16	Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
17	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
18	Pralhad T, Madhusudan S and Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol. 55:1045–1053. 2003. View Article : Google Scholar : PubMed/NCBI
19	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
20	Taylor RM, Kashima TG, Knowles HJ and Athanasou NA: VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology. Lab Invest. 92:1398–1406. 2012. View Article : Google Scholar : PubMed/NCBI
21	Knowles HJ and Athanasou NA: Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol. 215:56–66. 2008. View Article : Google Scholar : PubMed/NCBI
22	Wülling M, Delling G and Kaiser E: The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 34:983–993. 2003. View Article : Google Scholar : PubMed/NCBI
23	Morgan T, Atkins GJ, Trivett MK, et al: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 167:117–128. 2005. View Article : Google Scholar : PubMed/NCBI
24	Skubitz KM, Cheng EY, Clohisy DR, Thompson RC and Skubitz AP: Gene expression in giant-cell tumors. J Lab Clin Med. 144:193–200. 2004. View Article : Google Scholar : PubMed/NCBI
25	Atkins GJ, Haynes DR, Graves SE, et al: Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res. 15:640–649. 2000. View Article : Google Scholar : PubMed/NCBI
26	Cowan RW, Singh G and Ghert M: PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone. J Orthop Res. 30:877–884. 2012. View Article : Google Scholar
27	Xu M, Song ZG, Xu CX, et al: IL-17A stimulates the progression of giant cell tumors of bone. Clin Cancer Res. 19:4697–4705. 2013. View Article : Google Scholar : PubMed/NCBI
28	Rao VH, Singh RK, Delimont DC, et al: Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol. 14:291–300. 1999.PubMed/NCBI
29	Kumta SM, Huang L, Cheng YY, Chow LT, Lee KM and Zheng MH: Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 73:1427–1436. 2003. View Article : Google Scholar : PubMed/NCBI
30	Kudo N, Ogose A, Ariizumi T, et al: Expression of bone morphogenetic proteins in giant cell tumor of bone. Anticancer Res. 29:2219–2225. 2009.PubMed/NCBI
31	Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
32	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
33	Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI
34	Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
35	Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
36	Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012. View Article : Google Scholar : PubMed/NCBI
37	Zhao L, Chen X and Cao Y: New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai). 43:831–839. 2011. View Article : Google Scholar
38	Fan L, Wu Q, Xing X, Wei Y and Shao Z: MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 44:407–414. 2012. View Article : Google Scholar
39	Duan Z, Choy E, Harmon D, et al: MicroRNA-199a-3p is down-regulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 10:1337–1345
40	Pan Z, Sun X, Shan H, et al: MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 126:840–850. 2012. View Article : Google Scholar : PubMed/NCBI
41	Yuan J, Chen L, Chen X, Sun W and Zhou X: Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 40:2090–2097. 2012. View Article : Google Scholar
42	van der Deen M, Taipaleenmaki H, Zhang Y, et al: MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem. 288:21307–21319. 2013. View Article : Google Scholar : PubMed/NCBI
43	Mao JH, Zhou RP, Peng AF, et al: microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett. 4:1125–1129. 2012.PubMed/NCBI
44	Fasanaro P, Greco S, Lorenzi M, et al: An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 284:35134–35143. 2009. View Article : Google Scholar : PubMed/NCBI
45	Mizuno Y, Tokuzawa Y, Ninomiya Y, et al: miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. Febs Lett. 583:2263–2268. 2009. View Article : Google Scholar : PubMed/NCBI
46	Ramakrishnan A, Torok-Storb B and Pillai MM: Primary marrow-derived stromal cells: isolation and manipulation. Methods Mol Biol. 1035:75–101. 2013. View Article : Google Scholar : PubMed/NCBI
47	Wang XH, Zhao FJ, Han BM, et al: Primary stromal cells isolated from human various histological/pathological prostate have different phenotypes and tumor promotion role. Chin Med J (Engl). 124:1700–1707. 2011.
48	Zhao JH, Luo Y, Jiang YG, He DL and Wu CT: Knockdown of β-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Invest. 29:377–382. 2011. View Article : Google Scholar : PubMed/NCBI
49	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
50	Mutharasan RK, Nagpal V, Ichikawa Y and Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol. 301:H1519–H1530. 2011. View Article : Google Scholar : PubMed/NCBI
51	Biswas S, Roy S, Banerjee J, et al: Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA. 107:6976–6981. 2010. View Article : Google Scholar : PubMed/NCBI
52	Riggi N, Suvà ML, De Vito C, et al: EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 24:916–932. 2010. View Article : Google Scholar : PubMed/NCBI
53	Ban J, Jug G, Mestdagh P, et al: Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene. 30:2173–2180. 2011. View Article : Google Scholar : PubMed/NCBI
54	Zuntini M, Salvatore M, Pedrini E, et al: MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. Clin Genet. 78:507–516. 2010. View Article : Google Scholar : PubMed/NCBI
55	Mosakhani N, Pazzaglia L, Benassi MS, et al: MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. Histol Histopathol. 28:671–678. 2013.
56	Vogel S, Wottawa M, Farhat K, et al: Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem. 285:33756–33763. 2010. View Article : Google Scholar : PubMed/NCBI
57	Fujita N, Markova D, Anderson DG, et al: Expression of prolyl hydroxylases (PHDs) is selectively controlled by HIF-1 and HIF-2 proteins in nucleus pulposus cells of the intervertebral disc: distinct roles of PHD2 and PHD3 proteins in controlling HIF-1alpha activity in hypoxia. J Biol Chem. 287:16975–16986. 2012. View Article : Google Scholar : PubMed/NCBI
58	Demidenko ZN and Blagosklonny MV: The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1alpha. Cell Cycle. 10:1557–1562. 2011. View Article : Google Scholar : PubMed/NCBI
59	Kelly TJ, Souza AL, Clish CB and Puigserver P: A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol. 31:2696–2706. 2011. View Article : Google Scholar : PubMed/NCBI
60	Krock BL, Skuli N and Simon MC: Hypoxia-induced angio-genesis: good and evil. Genes Cancer. 2:1117–1133. 2011. View Article : Google Scholar